Brought to you by 
Mitsubishi gets rights to Vertex's VX-950 for hepatitis C
10 Aug 2021
Executive Summary
Mitsubishi Pharma has licensed exclusive development and marketing rights in Japan and Far Eastern countries to Vertex Pharmaceuticals' VX-950, an oral protease inhibitor in Phase I for the hepatitis C virus (HCV).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mitsubishi gets rights to Vertex's VX-950 for hepatitis C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice